BEACON_2B: BEACON, figure 2B

BEACON_2BR Documentation

BEACON, figure 2B

Description

Kaplan-Meier digitized data from BEACON, figure 2B (PMID 26482278). A reported sample size of 852 for a primary endpoint of OS in breast cancer.

Usage

BEACON_2B

Format

A data frame of 852 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (control, etirinotecan_pegol)

Source

Perez EA, Awada A, O’Shaughnessy J, et al. Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 1556–68.

Examples

summary(BEACON_2B)

kmplot(BEACON_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.